Downregulation of circ_0132266 in chronic lymphocytic leukemia promoted cell viability through miR-337-3p/PML axis | Zendy

Wei Wu | Zendy; Zijuan Wu | Zendy; Yi Xia | Zendy; Shuchao Qin | Zendy; Yue Li | Zendy; JiaZhu Wu | Zendy; JinHua Liang | Zendy; Li Wang | Zendy; Huayuan Zhu | Zendy; Lei Fan | Zendy; Jianxin Fu | Zendy; Wei Xu | Zendy; Hui Jin | Zendy; Jianyong Li | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Downregulation of circ_0132266 in chronic lymphocytic leukemia promoted cell viability through miR-337-3p/PML axis

Author(s) -

Wei Wu,

Zijuan Wu,

Yi Xia,

Shuchao Qin,

Yue Li,

JiaZhu Wu,

JinHua Liang,

Li Wang,

Huayuan Zhu,

Lei Fan,

Jianxin Fu,

Wei Xu,

Hui Jin,

Jianyong Li

Publication year - 2019

Publication title -

aging

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.473

H-Index - 90

ISSN - 1945-4589

DOI - 10.18632/aging.101997

Subject(s) - chronic lymphocytic leukemia , downregulation and upregulation , microrna , peripheral blood mononuclear cell , cancer research , leukemia , mechanism (biology) , biomarker , viability assay , cancer , biology , cell , gene , chemistry , immunology , genetics , in vitro , physics , quantum mechanics

Circular RNAs (circRNAs) have recently been reported to play crucial roles in various regulatory processes and involved in cancer onset and progression. However, the potential mechanism of circRNAs in chronic lymphocytic leukemia (CLL) remains largely unknown. Here, we observed hsa_circ_0132266 (circ_0132266), a circRNA significantly decreased in the peripheral blood mononuclear cells (PBMCs) of CLL patients compared with healthy donors, could act as an endogenous sponge of hsa-miR-337-3p (miR-337-3p) and regulate its activity, which resulted in a downstream change of target-gene PML and a consequent influence on cell viability. Taken together, our data indicated the regulatory mechanism of circ_0132266 in CLL progression through circ_0132266/miR-337-3p/PML axis, suggesting that it may serve as a biomarker as well as an exploitable therapeutic target for CLL.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research